JP2013503908A - ニューロキニン２受容体活性に関連する障害または疾患を治療するための化合物 - Google Patents

ニューロキニン２受容体活性に関連する障害または疾患を治療するための化合物 Download PDF

Info

Publication number
JP2013503908A
JP2013503908A JP2012528118A JP2012528118A JP2013503908A JP 2013503908 A JP2013503908 A JP 2013503908A JP 2012528118 A JP2012528118 A JP 2012528118A JP 2012528118 A JP2012528118 A JP 2012528118A JP 2013503908 A JP2013503908 A JP 2013503908A
Authority
JP
Japan
Prior art keywords
compound
disorder
compound according
pharmaceutically acceptable
acceptable salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2012528118A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013503908A5 (enExample
Inventor
ベイン，ジェラルド
サダボイ，ジョエル
チェン，ハオ
シェン，シャオユウ
Original Assignee
ユナイテッド パラゴン アソシエイツ インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ユナイテッド パラゴン アソシエイツ インコーポレイテッド filed Critical ユナイテッド パラゴン アソシエイツ インコーポレイテッド
Publication of JP2013503908A publication Critical patent/JP2013503908A/ja
Publication of JP2013503908A5 publication Critical patent/JP2013503908A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/02—Esters of acyclic saturated monocarboxylic acids having the carboxyl group bound to an acyclic carbon atom or to hydrogen
    • C07C69/22—Esters of acyclic saturated monocarboxylic acids having the carboxyl group bound to an acyclic carbon atom or to hydrogen having three or more carbon atoms in the acid moiety
    • C07C69/30—Esters of acyclic saturated monocarboxylic acids having the carboxyl group bound to an acyclic carbon atom or to hydrogen having three or more carbon atoms in the acid moiety esterified with trihydroxylic compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/003—Esters of saturated alcohols having the esterified hydroxy group bound to an acyclic carbon atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Psychiatry (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Addiction (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Pulmonology (AREA)
  • Reproductive Health (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
JP2012528118A 2009-09-04 2010-09-07 ニューロキニン２受容体活性に関連する障害または疾患を治療するための化合物 Pending JP2013503908A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US24001409P 2009-09-04 2009-09-04
US61/240,014 2009-09-04
PCT/US2010/048006 WO2011029099A1 (en) 2009-09-04 2010-09-07 Compounds for treating disorders or diseases associated with neurokinin 2 receptor activity

Publications (2)

Publication Number Publication Date
JP2013503908A true JP2013503908A (ja) 2013-02-04
JP2013503908A5 JP2013503908A5 (enExample) 2013-10-17

Family

ID=43649685

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2012528118A Pending JP2013503908A (ja) 2009-09-04 2010-09-07 ニューロキニン２受容体活性に関連する障害または疾患を治療するための化合物

Country Status (14)

Country Link
US (1) US20120190743A1 (enExample)
EP (1) EP2473038A4 (enExample)
JP (1) JP2013503908A (enExample)
KR (1) KR20120081120A (enExample)
CN (1) CN102740693A (enExample)
AU (1) AU2010289276A1 (enExample)
BR (1) BR112012004988A2 (enExample)
CA (1) CA2773035A1 (enExample)
MX (1) MX2012002551A (enExample)
NZ (1) NZ599215A (enExample)
RU (1) RU2012112943A (enExample)
SG (1) SG178964A1 (enExample)
WO (1) WO2011029099A1 (enExample)
ZA (1) ZA201202492B (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2508180A1 (en) * 2011-04-04 2012-10-10 Nestec S.A. Sn-1(3) Monoacylglycerides and lipid absorption
EP3027199B1 (en) 2013-08-01 2019-06-26 Dignify Therapeutics, LLC Compositions and methods for inducing urinary voiding and defecation
GB201315846D0 (en) 2013-09-05 2013-10-23 Imp Innovations Ltd Method for treating or preventing hot flushes

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1001A (en) * 1838-11-09 Open grate fobj burning coai
GB820954A (en) * 1956-05-02 1959-09-30 Beecham Res Lab Improvements in or relating to esters of 2,3-dimercaptopropanol
JPS505309A (enExample) * 1973-05-28 1975-01-21
JPH02131418A (ja) * 1988-11-10 1990-05-21 Sansho Seiyaku Co Ltd 外用剤
DE4204151A1 (de) * 1992-02-12 1993-08-19 Schneider Manfred Prof Dr Regioisomerenreine monoglyceride sowie ein verfahren zu ihrer herstellung durch enzymatische veresterung von glycerin in organischen loesungsmitteln
JP2003531818A (ja) * 1999-11-18 2003-10-28 エル ペダーソン リチャード フェロモン又はその成分のメタセシス合成方法
WO2009086634A1 (en) * 2008-01-11 2009-07-16 United Paragon Associates Inc. Fertilized egg isolate and use thereof

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3536809A (en) 1969-02-17 1970-10-27 Alza Corp Medication method
US3598123A (en) 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
US4008719A (en) 1976-02-02 1977-02-22 Alza Corporation Osmotic system having laminar arrangement for programming delivery of active agent
IE58110B1 (en) 1984-10-30 1993-07-14 Elan Corp Plc Controlled release powder and process for its preparation
US5073543A (en) 1988-07-21 1991-12-17 G. D. Searle & Co. Controlled release formulations of trophic factors in ganglioside-lipsome vehicle
IT1229203B (it) 1989-03-22 1991-07-25 Bioresearch Spa Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative.
US5120548A (en) 1989-11-07 1992-06-09 Merck & Co., Inc. Swelling modulated polymeric drug delivery device
US5733566A (en) 1990-05-15 1998-03-31 Alkermes Controlled Therapeutics Inc. Ii Controlled release of antiparasitic agents in animals
US5580578A (en) 1992-01-27 1996-12-03 Euro-Celtique, S.A. Controlled release formulations coated with aqueous dispersions of acrylic polymers
US5591767A (en) 1993-01-25 1997-01-07 Pharmetrix Corporation Liquid reservoir transdermal patch for the administration of ketorolac
IT1270594B (it) 1994-07-07 1997-05-07 Recordati Chem Pharm Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida
JPH0931020A (ja) * 1995-07-25 1997-02-04 Soda Koryo Kk グリセロールモノ−６−ヒドロキシアルカン酸エステル、及びこれを含有する香料組成物
SE9604582D0 (sv) * 1996-12-13 1996-12-13 Astra Ab Novel compounds
MY141736A (en) * 2002-10-08 2010-06-15 Elanco Animal Health Ireland Substituted 1,4-di-piperidin-4-yi-piperazine derivatives and their use as neurokinin antagonists
JO2676B1 (en) * 2004-04-06 2012-06-17 جانسين فارماسوتيكا ان. في Derivatives of second-aza-spiro- (5,4) -dikan and their use as antihistamines
CN1286529C (zh) * 2004-06-11 2006-11-29 华中科技大学 具有皮肤靶向性的药物组合物及其制备方法和用途
US7906147B2 (en) * 2006-10-12 2011-03-15 Nanoprobes, Inc. Functional associative coatings for nanoparticles

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1001A (en) * 1838-11-09 Open grate fobj burning coai
GB820954A (en) * 1956-05-02 1959-09-30 Beecham Res Lab Improvements in or relating to esters of 2,3-dimercaptopropanol
JPS505309A (enExample) * 1973-05-28 1975-01-21
JPH02131418A (ja) * 1988-11-10 1990-05-21 Sansho Seiyaku Co Ltd 外用剤
DE4204151A1 (de) * 1992-02-12 1993-08-19 Schneider Manfred Prof Dr Regioisomerenreine monoglyceride sowie ein verfahren zu ihrer herstellung durch enzymatische veresterung von glycerin in organischen loesungsmitteln
JP2003531818A (ja) * 1999-11-18 2003-10-28 エル ペダーソン リチャード フェロモン又はその成分のメタセシス合成方法
WO2009086634A1 (en) * 2008-01-11 2009-07-16 United Paragon Associates Inc. Fertilized egg isolate and use thereof

Non-Patent Citations (10)

* Cited by examiner, † Cited by third party
Title
JPN6014047112; ＡＳＫＡＲＩ，Ａ．　ｅｔ　ａｌ．: Ｂｉｏｃｈｉｍｉｃａ　ｅｔ　Ｂｉｏｐｈｙｓｉｃａ　Ａｃｔａ，　Ｂｉｏｍｅｍｂｒａｎｅｓ , 1991, ｐ．１２７-１３０ *
JPN6014047113; ＤＥＮＧ，Ｌ．　ｅｔ　ａｌ．: Ｊｏｕｒｎａｌ　ｏｆ　Ｃｈｒｏｍａｔｏｇｒａｐｈｙ　Ａ , 2008, ｐ．６７-７２ *
JPN6014047114; ＰＡＧＡＮＵＺＺＩ，Ｖ．: Ｌａ　Ｒｉｖｉｓｔａ　Ｉｔａｌｉａｎａ　ｄｅｌｌｅ　Ｓｏｓｔａｎｚｅ　Ｇｒａｓｓｅ , 1999, ｐ．４５７-４７１ *
JPN6014047116; ＺＨＡＯ，Ｑ．　ｅｔ　ａｌ．: Ｊｏｕｒｎａｌ　ｏｆ　Ｎａｔｕｒａｌ　Ｐｒｏｄｕｃｔｓ Ｖｏｌ．６６, 2003, ｐ．７２５-７２８ *
JPN6014047117; ＴＡＮＧ，Ｈ-Ｆ．　ｅｔ　ａｌ．: Ｄｉ-ｅｒ　Ｊｕｎｙｉ　Ｄａｘｕｅ　Ｘｕｅｂａｏ Ｖｏｌ．２３，　Ｎｏ．３, 2002, ｐ．２４６-２４９ *
JPN6014047119; ＤＥ　ＭＡＲＩＮＯ，Ｓ．　ｅｔ　ａｌ．: Ｐｈｙｔｏｃｈｅｍｉｓｔｒｙ Ｖｏｌ．６８, 2007, ｐ．１８０５-１８１２ *
JPN6014047122; ＳＯＮＮＥＴ，Ｐ．Ｅ．　ａｎｄ　ＭＯＯＲＥ，Ｇ．Ｇ．: Ｌｉｐｉｄｓ Ｖｏｌ．２４，　Ｎｏ．８, 1989, ｐ．７４３-７４５ *
JPN6014047123; ＡＶＥＴＡ，Ｒ．　ｅｔ　ａｌ．: Ｇａｚｚｅｔｔａ　Ｃｈｉｍｉｃａ　Ｉｔａｌｉａｎａ Ｖｏｌ．１１６, 1986, ｐ．６４９-６５２ *
JPN7014003182; ＣＯＬＥＭＡＮ，Ｂ．Ｅ．　ｅｔ　ａｌ．: Ｓｙｎｌｅｔｔ Ｎｏ．８, 2004, ｐ．１３３９-１３４２ *
JPN7014003183; ＩＧＬＥＳＩＡＳ，Ｌ．Ｅ．　ｅｔ　ａｌ．: Ｒｅｖｉｓｔａ　Ｌａｔｉｎｏａｍｅｒｉｃａｎａ　ｄｅ　Ｑｕｉｍｉｃａ Ｖｏｌ．２８，　Ｎｏ．２, 2000, ｐ．９５-９９ *

Also Published As

Publication number Publication date
BR112012004988A2 (pt) 2015-09-08
EP2473038A4 (en) 2013-10-23
MX2012002551A (es) 2012-09-07
RU2012112943A (ru) 2013-10-10
NZ599215A (en) 2014-11-28
SG178964A1 (en) 2012-04-27
CA2773035A1 (en) 2011-03-10
AU2010289276A1 (en) 2012-05-03
CN102740693A (zh) 2012-10-17
WO2011029099A1 (en) 2011-03-10
EP2473038A1 (en) 2012-07-11
KR20120081120A (ko) 2012-07-18
US20120190743A1 (en) 2012-07-26
ZA201202492B (en) 2013-02-27

Similar Documents

Publication Publication Date Title
KR101739800B1 (ko) 안드로겐 수용체 조절제의 에스터 유도체 및 그의 이용 방법
JP4993523B2 (ja) ２０（ｓ）−プロトパナキサジオールの抗うつ薬製造への使用
TW201026676A (en) A method of inhibiting hepatitis C virus by combination of a 5,6-dihydro-1H-pyridin-2-one and one or more additional antiviral compounds
JP6789578B2 (ja) ５−ｈｔ２ｃ受容体アゴニストおよび組成物、ならびに使用方法
KR101823451B1 (ko) 퀴논계 화합물, 이의 광학 이성질체 및 이의 제조 방법과 의약 용도
JP2019011343A (ja) 選択的ｓ１ｐ１レセプターアゴニストを含む薬学的合剤
JP6068457B2 (ja) 化合物及び組成物
CN110831584A (zh) 具有新颖的组合物、组合的靶向药物拯救及其方法
WO2023081895A1 (en) Isotopically enriched analogs of 5,6-methylenedioxy-2-aminoindane (mdai)
JP2013503908A (ja) ニューロキニン２受容体活性に関連する障害または疾患を治療するための化合物
JP2016508489A (ja) プロトパナキサジオール誘導体、その製造方法及びその応用
AU2015258814A1 (en) Clearance of amyloid ss
CN1859846A (zh) 白屈菜赤碱、其类似物及其在治疗躁郁症和其他认知紊乱中的应用
JP6262096B2 (ja) 受精卵分離物およびその使用
CN101475483A (zh) β-(3,4-二羟基苯基)-α-羟基丙酸酯类化合物的医药用途
JP6185650B2 (ja) ５−ｈｔ４受容体アゴニストとしての５−アミノ−キノリン−８−カルボキサミド誘導体
CN1627940A (zh) 肉桂酸二聚体,它们的制剂及其在治疗神经变性病中的应用
JP2015134732A (ja) 血管透過性亢進抑制剤
HK1177391A (en) Compounds for treating disorders or diseases associated with neurokinin 2 receptor activity
CN114225035A (zh) 环状RNA Cwc27下调剂在制备预防和/或治疗阿尔茨海默病的药物中的应用
JP2025530203A (ja) うつ病を処置するための方法
CN101555214B (zh) 苯基环丁基酰胺衍生物及其光学异构体、制备方法和用途
WO2024040259A2 (en) Thiazole derivatives for therapeutic use
CN1678300A (zh) 可用于治疗慢性髓细胞性白血病的药物组合物
JP2025500813A (ja) カンナビジオール誘導体、その調製方法及び使用

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130829

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20130829

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20141022

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20141111

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20150205

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20150305

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20150406

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20150714